Abstract | PURPOSE OF INVESTIGATION: Uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) represent more aggressive tumors than the more common endometroid cancers, exhibiting a propensity for distant metastasis. The aim of this study was to investigate the activity and safety of paclitaxel/ carboplatin chemotherapy as the only adjuvant treatment in patients with surgically resected UPSC and UCCC. METHODS: Fifteen patients with Stage IB-IV UPSC or UCCC were treated with a mean of six courses of paclitaxel 175 mg/m3 plus carboplatin AUC 5 at three-week intervals, three to six weeks after undergoing surgery with curative intent. No patient had residual disease after surgery and none underwent pre- or post- chemotherapy irradiation. RESULTS: With a median follow-up of 29.4 months, six patients (40%) relapsed and two (13%) died of disease. Mean time to recurrence was 16.9 months. Recurrence rate per Stage was 17% for Stage IB/C, 57% for Stage IIIA/C and 50% for Stage IV. Projected 5-year overall survival and progression-free survival was 79.7% and 55.7%, respectively. All relapses were abdominopelvic whereas in one case pelvic recurrence was accompanied by lung metastasis. The most frequent grade 3-4 toxicity was neutropenia. CONCLUSION:
|
Authors | G T Bozas, A Bamias, E Kastritis, A Rodolakis, G Vlahos, C A Papadimitriou, S Markaki, M A Dimopoulos |
Journal | European journal of gynaecological oncology
(Eur J Gynaecol Oncol)
Vol. 26
Issue 6
Pg. 627-31
( 2005)
ISSN: 0392-2936 [Print] Singapore |
PMID | 16398224
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adenocarcinoma, Clear Cell
(drug therapy, mortality)
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Carcinoma, Papillary
(drug therapy, mortality)
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Endometrial Neoplasms
(drug therapy, mortality)
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(epidemiology)
- Neoplasm Staging
- Paclitaxel
(administration & dosage, adverse effects)
- Survival Analysis
- Treatment Outcome
|